Nanobiotix S.A. (FRA:5NR)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.52B +247.3% |
| Revenue (ttm) | 32.59M |
| Net Income | -23.96M |
| EPS | -0.50 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 29.52 |
| Previous Close | 30.06 |
| Day's Range | 29.52 - 30.44 |
| 52-Week Range | 9.30 - 47.86 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 25, 2026 |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Th... [Read more]
Financial Performance
Financial StatementsNews
Nanobiotix assumed with a Buy at Guggenheim
Guggenheim assumed coverage of Nanobiotix (NBTX) with a Buy rating and $64 price target. The firm’s investment thesis is centered on the company’s first-in-class radio-enhancer, JNJ-1900, which is par...
Nanobiotix announces updated safety, efficacy data from JNJ-1900 study
Nanobiotix (NBTX) announced updated safety and efficacy data from the completed dose-escalation and expansion phases of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center…
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deem...
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approach...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Voting Rights and Shares Capital of the Company
PARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité d...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) In accordance with...
Nanobiotix Reports Q1 2026 Update; Expects Cash Runway Through 2029
(RTTNews) - Nanobiotix S.A. (NBTX), a clinical-stage biotechnology firm, reported a financial and operational update for its first quarter of 2026.
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
Nanobiotix Earnings release: Q1 2026
Nanobiotix released its Q1 2026 earnings on June 2, 2026, summarizing the period's financial results.
Nanobiotix Joins the Euronext Tech Leaders Index
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
NANOBIOTIX Announces Closing of Global Offering
PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-...
Nanobiotix Exercises Underwriters' Option In Global Offering, Gross Proceeds Reach $100 Mln
(RTTNews) - Nanobiotix S.A. (NBTX), a late-clinical stage company, on Friday announced that underwriters of its global offering had fully exercised the option to purchase additional American Depositar...
NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-...
Nanobiotix (NBTX) Sees a Significant Decline in Share Price
Nanobiotix (NBTX) Sees a Significant Decline in Share Price
Nanobiotix Announces Pricing Of Global Offering Worth $98 Mln
(RTTNews) - Nanobiotix S.A. (NBTX), a late-stage biotechnology company, on Thursday announced pricing of a follow-on global offering consisting of a public offering and an offering exclusively for qua...
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering ...
Nanobiotix Resumes Trading Of Ordinary Shares On Euronext Paris
(RTTNews) - Nanobiotix S.A. (NBTX), announced that, following a temporary halt earlier in that day, trading of its ordinary shares on Euronext Paris resumed at 3:30 p.m. Paris time (9:30 a.m. New York...
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-...
Nanobiotix Temporarily Halts Paris Trading Amid Global Offering; Stock Slides
(RTTNews) - Nanobiotix S.A. (NBTX), a late-stage clinical biotechnology company pioneering physics-based therapeutic approaches for cancer and other major diseases, said trading of its ordinary shares...
Nanobiotix (NBTX) Plans €75M Global Offering to Support Development Initiatives
Nanobiotix (NBTX) Plans €75M Global Offering to Support Development Initiatives
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-...
Nanobiotix (NBTX) Initiates €75 Million Global Follow-On Offering
Nanobiotix (NBTX) Initiates €75 Million Global Follow-On Offering
Nanobiotix announces EUR 75M global follow-on offering
Nanobiotix (NBTX) announces the launch, subject to market and other conditions, of an approximately EUR 75M global follow-on offering consisting of (i) a public offering of its American Depositary Sha...